In order to address whether PSMα3 can be used for therapeutic approaches by modulating moDCs for iTreg priming in a setting of T cell associated autoimmune diseases, moDCs from healthy donors were co-cultured after treatment with LPS or LPS + PSMα3 with CD4+ T cells from patients with spondyloarthritis (Figure 7A) and rheumatoid arthritis (RA) (data not shown). The gene discussed is PSMA3; the disease is spondyloarthropathy.